Generation Bio Co. (GBIO)

Market Cap	210.77M
Revenue (ttm)	5.90M
Net Income (ttm)	-126.61M
Shares Out	66.49M
EPS (ttm)	-1.96
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	62,156
Open	3.280
Previous Close	3.110
Day's Range	3.170 - 3.360
52-Week Range	0.860 - 6.980
Beta	2.79
Analysts	Buy
Price Target	8.00 (+152.37%)
Earnings Date	May 13, 2024

About GBIO

Generation Bio Co. develops non-viral genetic medicines for the treatment of rare and prevalent diseases. The company develops cell-targeted lipid nanoparticle (ctLNP) platform, a modular delivery system for nucleic acids to avoid off-target clearance by the liver and spleen that enables ctLNPs to persist in systemic circulation, which allows for highly selective and potent ligand-driven targeting to specific tissues and cell types; and novel immune-quiet DNA (iqDNA) to enable long-lasting high levels of gene expression from non-integrating epi...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 12, 2020
• Employees: 174
• Stock Exchange: NASDAQ
• Ticker Symbol: GBIO

Analyst Forecast

According to 5 analysts, the average rating for GBIO stock is "Buy." The 12-month stock price forecast is $8.0, which is an increase of 152.37% from the latest price.

Price Target

$8.0

(152.37% upside)

Analyst Consensus: Buy